List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1263783/publications.pdf Version: 2024-02-01



RENÃO HOUTMAN

#	Article	IF	CITATIONS
1	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell, 2016, 29, 846-858.	7.7	228
2	Short-Chain Fatty Acids Stimulate Angiopoietin-Like 4 Synthesis in Human Colon Adenocarcinoma Cells by Activating Peroxisome Proliferator-Activated Receptor γ. Molecular and Cellular Biology, 2013, 33, 1303-1316.	1.1	219
3	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell, 2018, 33, 173-186.e5.	7.7	201
4	Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension, 2018, 71, 599-608.	1.3	149
5	Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell, 2019, 178, 949-963.e18.	13.5	131
6	The Nuclear Receptor PPAR ^{î3} Controls Progressive Macrophage Polarization as a Ligand-Insensitive Epigenomic Ratchet of Transcriptional Memory. Immunity, 2018, 49, 615-626.e6.	6.6	128
7	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell, 2019, 35, 401-413.e6.	7.7	127
8	Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. ELife, 2014, 3, e02057.	2.8	113
9	Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7910-7915.	3.3	105
10	Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. Cancer Discovery, 2018, 8, 1176-1193.	7.7	81
11	Differential <i>in Vitro</i> Biological Action, Coregulator Interactions, and Molecular Dynamic Analysis of Bisphenol A (BPA), BPAF, and BPS Ligand–ERα Complexes. Environmental Health Perspectives, 2018, 126, 017012.	2.8	74
12	The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. Molecular Cancer Therapeutics, 2016, 15, 1702-1712.	1.9	73
13	The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. ELife, 2018, 7, .	2.8	72
14	Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor Î ³ Cofactor. Molecular and Cellular Proteomics, 2009, 8, 2212-2226.	2.5	66
15	Estrogenic Effects in the Immature Rat Uterus after Dietary Exposure to Ethinylestradiol and Zearalenone Using a Systems Biology Approach. Toxicological Sciences, 2007, 99, 303-314.	1.4	56
16	The AF-1-deficient estrogen receptor ERα46 isoform is frequently expressed in human breast tumors. Breast Cancer Research, 2016, 18, 123.	2.2	50
17	A Mixed Glucocorticoid/Mineralocorticoid Selective Modulator With Dominant Antagonism in the Male Rat Brain. Endocrinology, 2015, 156, 4105-4114.	1.4	48
18	Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 6764-6780.	3.2	46

#	Article	IF	CITATIONS
19	Binding of bisphenol A, bisphenol AF, and bisphenol S on the androgen receptor: Coregulator recruitment and stimulation of potential interaction sites. Toxicology in Vitro, 2017, 44, 287-302.	1.1	44
20	Predictive features of ligandâ€specific signaling through the estrogen receptor. Molecular Systems Biology, 2016, 12, 864.	3.2	41
21	Corticosteroid Action in the Brain: The Potential of Selective Receptor Modulation. Neuroendocrinology, 2019, 109, 266-276.	1.2	41
22	Lung proteome alterations in a mouse model for nonallergic asthma. Proteomics, 2003, 3, 2008-2018.	1.3	40
23	Serine-305 Phosphorylation Modulates Estrogen Receptor Alpha Binding to a Coregulator Peptide Array, with Potential Application in Predicting Responses to Tamoxifen. Molecular Cancer Therapeutics, 2012, 11, 805-816.	1.9	38
24	Understanding stress-effects in the brain via transcriptional signal transduction pathways. Neuroscience, 2013, 242, 97-109.	1.1	37
25	Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Review of Clinical Pharmacology, 2022, 15, 121-137.	1.3	33
26	Robust Array-Based Coregulator Binding Assay Predicting ERα-Agonist Potency and Generating Binding Profiles Reflecting Ligand Structure. Chemical Research in Toxicology, 2013, 26, 336-346.	1.7	28
27	Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor. Chemical Research in Toxicology, 2014, 27, 304-308.	1.7	28
28	Extending an In Vitro Panel for Estrogenicity Testing: The Added Value of Bioassays for Measuring Antiandrogenic Activities and Effects on Steroidogenesis. Toxicological Sciences, 2014, 141, 78-89.	1.4	27
29	Profiling of 3696 Nuclear Receptor–Coregulator Interactions: A Resource for Biological and Clinical Discovery. Endocrinology, 2018, 159, 2397-2407.	1.4	27
30	ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. Oncotarget, 2018, 9, 6924-6937.	0.8	27
31	The effect of glucuronidation on isoflavone induced estrogen receptor (ER)α and ERβ mediated coregulator interactions. Journal of Steroid Biochemistry and Molecular Biology, 2015, 154, 245-253.	1.2	24
32	A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 145-157.	0.9	22
33	Cofactor Profiling of the Glucocorticoid Receptor from a Cellular Environment. Methods in Molecular Biology, 2014, 1204, 83-94.	0.4	20
34	Cell proliferation and modulation of interaction of estrogen receptors with coregulators induced by ERα and ERβ agonists. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 376-385.	1.2	18
35	Dual-mechanism estrogen receptor inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
36	The selective glucocorticoid receptor antagonist CORT125281 has tissue-specific activity. Journal of Endocrinology, 2020, 246, 79-92.	1.2	16

#	Article	IF	CITATIONS
37	Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity. Scientific Reports, 2017, 7, 10633.	1.6	15
38	Asthma, the ugly duckling of lung disease proteomics?. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 815, 285-294.	1.2	14
39	Development of a new class of liver receptor homolog-1 (LRH-1) agonists by photoredox conjugate addition. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127293.	1.0	14
40	A Model of Glucocorticoid Receptor Interaction With Coregulators Predicts Transcriptional Regulation of Target Genes. Frontiers in Pharmacology, 2019, 10, 214.	1.6	13
41	Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer. Cancers, 2021, 13, 2486.	1.7	13
42	Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies. Oncotarget, 2017, 8, 109675-109691.	0.8	13
43	Attenuation of Very Late Antigen-5-Mediated Adhesion of Bone Marrow-Derived Mast Cells to Fibronectin by Peptides with Inverted Hydropathy to EF-Hands. Journal of Immunology, 2001, 166, 861-867.	0.4	12
44	Natural helix 9 mutants of PPARÎ ³ differently affect its transcriptional activity. Molecular Metabolism, 2019, 20, 115-127.	3.0	12
45	Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. Nature Chemical Biology, 2021, 17, 307-316.	3.9	11
46	Co-activator candidate interactions for orphan nuclear receptor NR2E1. BMC Genomics, 2016, 17, 832.	1.2	10
47	Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads. Frontiers in Immunology, 2017, 8, 1324.	2.2	10
48	Destabilization of the torsioned conformation of a ligand side chain inverts the LXRβ activity. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1577-1586.	1.2	9
49	Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant. Chemico-Biological Interactions, 2014, 220, 222-230.	1.7	8
50	Differential modulation of FXR activity by chlorophacinone and ivermectin analogs. Toxicology and Applied Pharmacology, 2016, 313, 138-148.	1.3	8
51	A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor α in an MCF-7 Microarray Compendium. Chemical Research in Toxicology, 2021, 34, 313-329.	1.7	8
52	A phospholipid mimetic targeting LRH-1 ameliorates colitis. Cell Chemical Biology, 2022, 29, 1174-1186.e7.	2.5	8
53	Characterization of the differential coregulator binding signatures of the Retinoic Acid Receptor subtypes upon (ant)agonist action. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 1195-1206.	1.1	7
54	The effects of <i>all-trans</i> retinoic acid on estrogen receptor signaling in the estrogen-sensitive MCF/BUS subline. Journal of Receptor and Signal Transduction Research, 2018, 38, 112-121.	1.3	7

#	Article	IF	CITATIONS
55	A mutant form of ERα associated with estrogen insensitivity affects the coupling between ligand binding and coactivator recruitment. Science Signaling, 2020, 13, .	1.6	5
56	Cholestenoic acid analogues as inverse agonists of the liver X receptors. Journal of Steroid Biochemistry and Molecular Biology, 2020, 199, 105585.	1.2	4
57	Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice. Molecular Metabolism, 2021, 48, 101225.	3.0	4
58	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of <i>ESR1</i> Activating Mutations. SSRN Electronic Journal, 0, , .	0.4	0